Table 7.

Nilotinib pediatric leukemia trials in http://www.clinicaltrials.gov

Number	Abbreviated title	NCT number	Age	Sponsor
1	Nilotinib in Ph+ CML children	01844765	1–18 years	Novartis
2	PK of nilotinib in Ph+ CML or ALL children	01077544	1–18 years	Novartis
3	Nilotinib and imatinib in ALL or CLL after donor SCT	00702403	?	Fred Hutchinson CRC
4	Nilotinib and combination CT in newly-diagnosed ALL	00844298	≥15 years	AMC, Korea
5	h–Igf-1 axis in CML children in remission	01901666	?	PIMER, India
6	Nilotinib vs imatinib in CML	00760877	≥17 years	Novartis
7	CT + irradiation + PBSCT in AML or ALL respondent to a TKI	00036738	≤70 years	Fred Hutchinson CRC
8	Nilotinib in CML Phase II study	00129740	≥16 years	MD Anderson Cancer Center
9	Imatinib vs nilotinib in CML	00802841	≥16 years	Novartis
10	Decision on imatinib vs other TKI in CML	01762969	≥16 years	Rabin Medical Center

Notes: One study (NCT0132170) tested pegylated interferon-alfa 2a in TKD-treated adolescents and adults; one study (NCT01460498) investigated azacytidine in MRD CML treated with a TKI. The TKIs were not part of the experimental investigation. Study NCT01698905 included only adult patients. The three studies were not included in the table.

Abbreviations: NCT, National Clinical Trial; Ph+, Philadelphia chromosome-positive; CML, chronic myeloid leukemia; PK, pharmacokinetics; ALL, acute lymphoblastic leukemia; CLL, chronic lymphoblastic leukemia; SCT, stem cell transplantation; CRC, Cancer Research Center; CT, chemotherapy; AMC, Asian Medical Center; PIMER, Postgraduate Institute of Medical Education and Research; PBSCT, peripheral blood stem cell transplantation; AML, acute myeloid leukemia; TKI, tyrosine kinase inhibitor; MRD, minimal residual disease.